bioRxiv · 10.1101/2021.03.05.434089
Neutralization heterogeneity of United Kingdom and South-African SARS CoV-2 variants in BNT162b2-vaccinated or convalescent COVID-19 healthcare workers
Abstract
There are concerns about neutralizing antibodies (NAb) potency against the newly emerged VOC202012/01 (UK) and 501Y.V2 (SA) SARS-CoV-2 variants in mRNA-vaccinated subjects and in recovered COVID-19 patients. We used a viral neutralization test with a strict 100% neutralizing criterion on UK and SA clinical isolates in comparison with a globally distributed D614G SARS-CoV-2 strain. In two doses BNT162b2-vaccinated healthcare workers (HCW), despite heterogeneity in neutralizing capacity against the three SARS-CoV-2 strains, most of the sera harbored at least a NAb titer [≥] 1:10 suggesting a certain humoral protection activity either on UK or SA variants. However, six months after mild forms of COVID-19, an important proportion of HCW displayed no neutralizing activity against SA strain. This result supports strong recommendations for vaccination of previously infected subjects.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Marot, S. S., Malet, I., Jary, A., Leducq, V., Abdi, B., Teyssou, E., Soulie, C., Wirden, M., Rodriguez, C., Fourati, S., Pawlotsky, J.-M., Boutolleau, D., Burrel, S., Calvez, V., Marcelin, A.-G.. 2021-03-05. Neutralization heterogeneity of United Kingdom and South-African SARS CoV-2 variants in BNT162b2-vaccinated or convalescent COVID-19 healthcare workers. https://doi.org/10.1101/2021.03.05.434089
Cite the original work for its findings. Save a collection to share your selection of sources.